Quarterly ResultAug 11, 2026, 04:23 PM
Aquestive H1 Revenue +51% to $28.3M; Q2 Net Loss $(22.9)M from Debt Extinguishment
AI Summary
Aquestive Therapeutics reported a 51% increase in revenue for the first six months of 2026, reaching $28.265 million, with net loss improving to $(30.921) million year-over-year. For the second quarter of 2026, revenue grew 38% to $13.819 million, but the company posted a net loss of $(22.864) million, primarily due to an $11.683 million loss on extinguishment of debt. The company also secured $54.337 million in new long-term debt and repaid $45 million of existing debt.
Key Highlights
- H1 2026 revenue increased 51% to $28.265 million from H1 2025.
- Q2 2026 revenue increased 38% to $13.819 million from Q2 2025.
- H1 2026 net loss improved to $(30.921) million from $(36.478) million.
- Q2 2026 net loss was $(22.864) million, including $(11.683) million debt extinguishment loss.
- Secured $54.337 million in new long-term debt; repaid $45 million of 13.5% Notes.
- Cash and cash equivalents stood at $98.490 million as of June 30, 2026.
- US revenues for H1 2026 more than doubled to $24.236 million.
Price Impact
More from AQST